

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0287 |
| Estimated average burden hours per response: | 0.5 |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See instruction 10.

| | | |
|---|--|--|
| 1. Name and Address of Reporting Person* <u>Secora Michael</u> <hr/> (Last) (First) (Middle) C/O RECURSION PHARMACEUTICALS 41 S. RIO GRANDE STREET <hr/> (Street) SALT LAKE CITY UT 84101 <hr/> (City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol <u>RECURSION PHARMACEUTICALS, INC. [RRRX]</u> | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Financial Officer |
| | 3. Date of Earliest Transaction (Month/Day/Year) 09/10/2024 | |
| 4. If Amendment, Date of Original Filed (Month/Day/Year) | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|-------------------------|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Class A Common Stock | 09/10/2024 | | M ⁽¹⁾ | | 39,375 | A | \$2.22 | 1,392,756 | D | |
| Class A Common Stock | 09/10/2024 | | S ⁽¹⁾ | | 15,000 | D | \$6.1666 ⁽²⁾ | 1,377,756 | D | |
| Class A Common Stock | 09/11/2024 | | M ⁽¹⁾ | | 39,375 | A | \$2.22 | 1,417,131 | D | |
| Class A Common Stock | 09/11/2024 | | S ⁽¹⁾ | | 15,000 | D | \$6.3153 ⁽³⁾ | 1,402,131 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
|--|--|--------------------------------------|--|--------------------------------|---|--|--|-----------------|---|--|--|---|--|-------|
| | | | | Code | V | | Date Exercisable | Expiration Date | | | | | | Title |
| Stock Option (Right to Buy) | \$2.22 | 09/10/2024 | | M ⁽¹⁾ | | 39,375 | (4) | 03/03/2030 | Class A Common Stock | 39,375 | \$0 | 534,510 | D | |
| Stock Option (Right to Buy) | \$2.22 | 09/11/2024 | | M ⁽¹⁾ | | 39,375 | (4) | 03/03/2030 | Class A Common Stock | 39,375 | \$0 | 495,135 | D | |
| Stock Option (Right to Buy) | \$2.22 | | | | | | (5) | 03/03/2030 | Class A Common Stock | 0 | | 685,177 | D | |
| Stock Option (Right to Buy) | \$11.4 | | | | | | | 02/04/2022 | 02/04/2032 | Class A Common Stock | 0 | 3,914 | D | |
| Stock Option (Right to Buy) | \$11.4 | | | | | | (6) | 02/04/2032 | Class A Common Stock | 0 | | 116,684 | D | |
| Stock Option (Right to Buy) | \$8.55 | | | | | | (7) | 02/01/2033 | Class A Common Stock | 0 | | 404,857 | D | |
| Stock Option (Right to Buy) | \$10.09 | | | | | | (8) | 02/09/2034 | Class A Common Stock | 0 | | 348,380 | D | |

Explanation of Responses:

1. Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2024.

2. This transaction was executed in multiple trades at prices ranging from \$6.06 to \$6.31. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. This transaction was executed in multiple trades at prices ranging from \$6.18 to \$6.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
4. The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events.
5. The option, originally for 1,125,000 shares, vests as to one forty-eighth (1/48th) of the shares subject to the award one month after March 1, 2020, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter.
6. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
7. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
8. The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.

Remarks:

/s/Jonathan Golightly, attorney-in-fact 09/12/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.